Skip to main content

Research Repository

Advanced Search

Victoria: A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Centre Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerlCiguaT Gloobal Study in Subjects With Heart Failure With Reduced Ejection Fraction

People Involved

Professor Andrew Clark

Project Description

This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven trial of MK-1242 (vericiguat) in subjects with heart failure with reduced ejection
fraction (HFrEF).
Approximately 4872 subjects will be randomized globally in this trial to evaluate the efficacy and safety of MK-1242 (vericiguat) compared with placebo, on a background of standard of care.
After a screening phase of up to 30 days, eligible subjects will be treated until the required number of cardiovascular (CV) death events is observed (estimated median follow -up duration of approximately 18 months). All subjects will be followed until study completion to assess for the occurrence of endpoint events. Clinical outcome events will be adjudicated by an independent clinical events committee (CEC). An independent Data Safety and
Monitoring Board (DSMB) will monitor efficacy and safety data.

Type of Project Clinical Trial
Project Acronym Victoria
Status Project Complete
Funder(s) Merck, Sharp and Dohme (UK) Ltd
Value £77,200.00
Project Dates Jan 11, 2017 - Jan 31, 2022

You might also like

IRONMAN: Effectiveness of Intravenous iron treatment vs standard care in patients with heart failure and iron deficiency: a randomised, open-label multicentre trial May 5, 2017 - Aug 31, 2022
A BHF funded study to compare the effect of additional intravenous iron IV therapy versus standard therapy for patients with chronic heart failure and left ventricular systolic dysfunction and iron deficiency.
Recruitment is 12 patients per year - w... Read More about IRONMAN: Effectiveness of Intravenous iron treatment vs standard care in patients with heart failure and iron deficiency: a randomised, open-label multicentre trial.